{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:35:08Z","timestamp":1786980908669,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10637-020-00950-1","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T17:02:27Z","timestamp":1589994147000},"page":"1784-1795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma"],"prefix":"10.1007","volume":"38","author":[{"given":"David A.","family":"Reardon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rixe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Alekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie Turich","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Lassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"950_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/neuonc\/nou087","volume":"16","author":"QT Ostrom","year":"2014","unstructured":"Ostrom QT, Bauchet L, Davis FG et al (2014) The epidemiology of glioma in adults: a \u201cstate of the science\u201d review. Neuro-Oncology 16:896\u2013913. https:\/\/doi.org\/10.1093\/neuonc\/nou087","journal-title":"Neuro-Oncology"},{"issue":"suppl 2","key":"950_CR2","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","volume":"15","author":"QT Ostrom","year":"2013","unstructured":"Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006\u20132010. Neuro Oncol 15(suppl 2):ii1-i56. https:\/\/doi.org\/10.1093\/neuonc\/not151","journal-title":"Neuro Oncol"},{"issue":"suppl 3","key":"950_CR3","doi-asserted-by":"publisher","first-page":"iii93","DOI":"10.1093\/annonc\/mdu050","volume":"25","author":"R Stupp","year":"2014","unstructured":"Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(suppl 3):iii93-i101. https:\/\/doi.org\/10.1093\/annonc\/mdu050","journal-title":"Ann Oncol"},{"key":"950_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"950_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466. https:\/\/doi.org\/10.1016\/s1470-2045(09)70025-7","journal-title":"Lancet Oncol"},{"key":"950_CR6","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.2174\/092986711795656108","volume":"18","author":"S Lancellotti","year":"2011","unstructured":"Lancellotti S, Novarese L, De Cristofaro R (2011) Biochemical properties of indoleamine 2,3-dioxygenase: from structure to optimized design of inhibitors. Curr Med Chem 18:2205\u20132214. https:\/\/doi.org\/10.2174\/092986711795656108","journal-title":"Curr Med Chem"},{"key":"950_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","volume":"478","author":"CA Opitz","year":"2011","unstructured":"Opitz CA, Litzenburger UM, Sahm F et al (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197\u2013203. https:\/\/doi.org\/10.1038\/nature10491","journal-title":"Nature"},{"key":"950_CR8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri1457","volume":"4","author":"AL Mellor","year":"2004","unstructured":"Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:762\u2013774. https:\/\/doi.org\/10.1038\/nri1457","journal-title":"Nat Rev Immunol"},{"key":"950_CR9","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269\u20131274. https:\/\/doi.org\/10.1038\/nm934","journal-title":"Nat Med"},{"key":"950_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","volume":"34","author":"DH Munn","year":"2013","unstructured":"Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34:137\u2013143. https:\/\/doi.org\/10.1016\/j.it.2012.10.001","journal-title":"Trends Immunol"},{"key":"950_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1158\/2326-6066.Cir-15-0095","volume":"3","author":"N van Baren","year":"2015","unstructured":"van Baren N, Van den Eynde BJ (2015) Tumoral immune resistance mediated by enzymes that degrade tryptophan. Cancer Immunol Res 3:978\u2013985. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0095","journal-title":"Cancer Immunol Res"},{"key":"950_CR12","doi-asserted-by":"publisher","unstructured":"Okamoto A, Nikaido T, Ochiai K et al (2005) Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11:6030\u20136039. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-2671","DOI":"10.1158\/1078-0432.Ccr-04-2671"},{"key":"950_CR13","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1158\/1078-0432.Ccr-05-1966","volume":"12","author":"G Brandacher","year":"2006","unstructured":"Brandacher G, Perathoner A, Ladurner R et al (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12:1144\u20131151. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-1966","journal-title":"Clin Cancer Res"},{"key":"950_CR14","doi-asserted-by":"publisher","unstructured":"Mitsuka K, Kawataki T, Satoh E, Asahara T, Horikoshi T, Kinouchi H (2013) Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery 72:1031\u20131038; discussion 1038\u20131039. https:\/\/doi.org\/10.1227\/NEU.0b013e31828cf945","DOI":"10.1227\/NEU.0b013e31828cf945"},{"key":"950_CR15","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1158\/1078-0432.Ccr-12-2130","volume":"18","author":"DA Wainwright","year":"2012","unstructured":"Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, Tobias AL, Han Y, Lesniak MS (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18:6110\u20136121. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-2130","journal-title":"Clin Cancer Res"},{"key":"950_CR16","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1158\/1535-7163.Mct-17-1104","volume":"17","author":"B Gomes","year":"2018","unstructured":"Gomes B, Driessens G, Bartlett D et al (2018) Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271\/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy. Mol Cancer Ther 17:2530\u20132542. https:\/\/doi.org\/10.1158\/1535-7163.Mct-17-1104","journal-title":"Mol Cancer Ther"},{"key":"950_CR17","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1021\/acs.jmedchem.7b00974","volume":"60","author":"S Crosignani","year":"2017","unstructured":"Crosignani S, Bingham P, Bottemanne P et al (2017) Discovery of a novel and selective indoleamine 2,3-dioxygenase (IDO-1) inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271\/PF-06840003) and its characterization as a potential clinical candidate. J Med Chem 60:9617\u20139629. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00974","journal-title":"J Med Chem"},{"key":"950_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/jco.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280. https:\/\/doi.org\/10.1200\/jco.1990.8.7.1277","journal-title":"J Clin Oncol"},{"key":"950_CR19","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/jco.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol 28:1963\u20131972. https:\/\/doi.org\/10.1200\/jco.2009.26.3541","journal-title":"J Clin Oncol"},{"key":"950_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"54","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 54:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"950_CR21","doi-asserted-by":"publisher","unstructured":"Beatty GL, O\u2019Dwyer PJ, Clark J et al (2017) First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res 23:3269\u20133276. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2272","DOI":"10.1158\/1078-0432.Ccr-16-2272"},{"key":"950_CR22","doi-asserted-by":"publisher","first-page":"CT116","DOI":"10.1158\/1538-7445.AM2017-CT116","volume":"77","author":"LL Siu","year":"2017","unstructured":"Siu LL, Gelmon K, Chu Q et al (2017) Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1\/2a trial. Cancer Res 77:CT116. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-CT116","journal-title":"Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00950-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00950-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00950-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T23:49:53Z","timestamp":1678492193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00950-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["950"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00950-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"7 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DA Reardon declares research support (paid to DFCI): Acerta Phamaceuticals, Agenus, Celldex, EMD Serono, Incyte, Inovio, Midatech, Omniox, and Tragara; Advisory\/consultation (paid to Dr Reardon): AbbVie, Advantagene, Agenus, Amgen, Bayer, Bristol-Myers Squibb, Celldex, DelMar, EMD Serono, Genentech\/Roche, Inovio, Merck, Merck KGaA, Monteris, Novocure, Oncorus, Oxigene, Regeneron, Stemline, and Taiho Oncology Inc; Honoraria (paid to Dr Reardon): AbbVie, Advantagene, Agenus, Bristol-Myers Squibb, Celldex, EMD Serono, Genentech\/Roche, Inovio, Merck, Merck KGaA, Monteris, Novocure, Oncorus, Oxigene, Regeneron, Stemline, and Taiho Oncology Inc; A Desjardins declares research research support (paid to Duke): Orbus Therapeutics, Genentech\/Roche, Triphase Accelerator, Symphogen A\/S; has served as consultant\/participated in advisory boards (paid to Dr Desjardins: Orbus Therapeutics and Istari Oncology; as stock options in Istari Oncology; and patent on the use of the oncolytic poliovirus for the treatment of solid tumors; T Cloughesy declares research support from AstraZeneca, honoraria from Roche for serving on the Speakers Bureau, has served as a consultant\/participated in advisory boards for VBL, Bayer, GW Pharma, Tocagen, Del Mar, Amgen, QED, Merck, Karyopharm, Odonate, Pascal Biosciences, Agios, is a Board member for Global Coalition for Adaptive Research 501 \u00a93, has stock options with Notable Labs, has a provisional patent application for compositions and methods for treating cancer; O Rixe declares research support from: Kyowa\/Kirin, Oxford Biotherapeutics, Nanobiotix, IMV Inc, Newlink, Seattle Genetics, has served on the advisory committee for Kyowa\/Kirin, Bexion, and is a stock shareholder in Bexion; S Alekar is an employee of Pfizer and hold stock in Pfizer, JH Williams is an employee of Pfizer and hold stock in Pfizer, CT Taylor is an employee of Pfizer and hold stock in Pfizer, R Li is an employee of Pfizer and hold stock in Pfizer; AB Lassman declares grants and non-financial support from Pfizer, during the conduct of the study; personal fees and non-financial support from Bioclinica as an expert blinded independent reviewer of clinical and imaging data for a BMS-sponsored trial, grants, personal fees and non-financial support from Karyopharm, personal fees from Sapience, personal fees from Magnolia Innovation, personal fees and non-financial support from Guidepoint Global, personal fees and non-financial support from Abbott Molecular, grants, personal fees and non-financial support from QED Therapeutics, personal fees from GLG, personal fees from Olson Research Group, personal fees from Biostrategies Group, personal fees and non-financial support from Forma, personal fees from Clarion Health Care Consulting, grants, personal fees and non-financial support from Bayer, personal fees from Defined Health, personal fees from Research America, personal fees from Advanced Focus, personal fees from Expert Connect, personal fees from Elsevier, grants, personal fees and non-financial support from Orbus, personal fees and non-financial support from Northwest Biotherapeutics, grants, personal fees and non-financial support from AbbVie, personal fees from Bionest Partners, personal fees from Antheneum, personal fees from DecioBio, personal fees from Connected Research and Consulting, personal fees from Health Advisors Bureau\/Medefield, grants, personal fees and non-financial support from Agios, personal fees from RICCA Group, personal fees from Medsurvey, personal fees from Focus Forward Incentives, personal fees from WebMD, personal fees from Celgene, personal fees from prIME Oncology, personal fees from marketplusresearch.com, personal fees from Market Strategies International, personal fees from MSI Survey, personal fees from Cortice Biosciences, grants, personal fees and non-financial support from Kadmon, personal fees from Schlesinger Associates, personal fees and non-financial support from Novocure, personal fees and non-financial support from Physicians' Education Resource\/Chemotherapy Foundation Symposium, grants and non-financial support from Genentech\/Roche, grants and non-financial support from Amgen, grants and non-financial support from Millienium, grants and non-financial support from Celldex, grants and non-financial support from Novartis, non-financial support from Keryx as legacy to Aeterna Zentaris, grants and non-financial support from VBI Vaccines, grants and non-financial support from Beigene, grants and non-financial support from Oncoceutics, non-financial support from Tocagen, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"<i>Research involving human participants<\/i>: The study was approved by the institutional review board or independent ethics committee of each participating center and followed the Declaration of Helsinki and International Council for Harmonization Good Clinical Practice guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects or legally authorized representatives provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}